挑战范式。
Challenging the paradigm.
作者信息
Everard Mark L
机构信息
Paediatric Respiratory Medicine, University of Western Australia, Perth, Australia.
出版信息
Breathe (Sheff). 2022 Mar;18(1):210148. doi: 10.1183/20734735.0148-2021. Epub 2021 Mar 8.
Abstract
摘要
https://bit.ly/30VkP8Q. （此为链接，无法直接完整翻译，保留原文形式）
相似文献
1
Challenging the paradigm.
Breathe (Sheff). 2022 Mar;18(1):210148. doi: 10.1183/20734735.0148-2021. Epub 2021 Mar 8.
2
Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis.
ERJ Open Res. 2023 Aug 29;9(4). doi: 10.1183/23120541.00356-2023. eCollection 2023 Jul.
3
Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report.
Eur Respir J. 2019 May 9;53(5). doi: 10.1183/13993003.02058-2018. Print 2019 May.
4
Reply to: Challenging the paradigm.
Breathe (Sheff). 2022 Mar;18(1):210174. doi: 10.1183/20734735.0174-2021. Epub 2021 Mar 8.
5
Get a move on: physical (in)activity in people with obstructive airway disease.
ERJ Open Res. 2024 Jul 22;10(4). doi: 10.1183/23120541.00305-2024. eCollection 2024 Jul.
6
De-labelling severe asthma diagnosis: the challenge of DIPNECH.
ERJ Open Res. 2022 Feb 7;8(1). doi: 10.1183/23120541.00485-2021. eCollection 2022 Jan.
7
Is asthma a risk factor for COVID-19? Are phenotypes important?
ERJ Open Res. 2021 Jan 25;7(1). doi: 10.1183/23120541.00216-2020. eCollection 2021 Jan.
8
Targeting treatable traits in severe asthma: a randomised controlled trial.
Eur Respir J. 2020 Mar 5;55(3). doi: 10.1183/13993003.01509-2019. Print 2020 Mar.
9
Treatment burden is important to patients but often overlooked by clinicians.
Breathe (Sheff). 2021 Mar;17(1):210031. doi: 10.1183/20734735.0031-2021.
10
The changing face of the modern respiratory clinician.
Breathe (Sheff). 2023 Sep;19(3):230147. doi: 10.1183/20734735.0147-2023. Epub 2023 Sep 12.
本文引用的文献
1
Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease.
Breathe (Sheff). 2021 Sep;17(3):210053. doi: 10.1183/20734735.0053-2021.
2
Time to Say Goodbye to Bronchiolitis, Viral Wheeze, Reactive Airways Disease, Wheeze Bronchitis and All That.
Front Pediatr. 2020 May 5;8:218. doi: 10.3389/fped.2020.00218. eCollection 2020.
3
Asthma: A Loss of Post-natal Homeostatic Control of Airways Smooth Muscle With Regression Toward a Pre-natal State.
Front Pediatr. 2020 Apr 16;8:95. doi: 10.3389/fped.2020.00095. eCollection 2020.
4
Preventing asthma deaths: above all, do no harm.
Lancet Respir Med. 2019 Sep;7(9):732-733. doi: 10.1016/S2213-2600(19)30197-3. Epub 2019 Jun 25.
5
Idiopathic chronic productive cough and response to open-label macrolide therapy: An observational study.
Respirology. 2019 Jun;24(6):558-565. doi: 10.1111/resp.13483. Epub 2019 Feb 5.
6
Persistent and Recurrent Bacterial Bronchitis-A Paradigm Shift in Our Understanding of Chronic Respiratory Disease.
Front Pediatr. 2017 Feb 15;5:19. doi: 10.3389/fped.2017.00019. eCollection 2017.
7
Use of sputum eosinophil counts to guide management in children with severe asthma.
Thorax. 2012 Mar;67(3):193-8. doi: 10.1136/thx.2010.156836. Epub 2011 Aug 8.
8
A 10 year asthma programme in Finland: major change for the better.
Thorax. 2006 Aug;61(8):663-70. doi: 10.1136/thx.2005.055699.
9
Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum.
Lancet. 1958 Dec 13;2(7059):1245-7. doi: 10.1016/s0140-6736(58)91385-0.
10
Non-eosinophilic asthma: importance and possible mechanisms.
Thorax. 2002 Jul;57(7):643-8. doi: 10.1136/thorax.57.7.643.
Zotero 插件